Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The study, officially titled A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan, looks at how well tirzepatide works when started before Ramadan. It focuses on adults with type 2 diabetes who fast, a large and important real world group for diabetes care.
The only treatment in the trial is tirzepatide, a once weekly injectable drug from Eli Lilly. It is designed to improve blood sugar control and support weight loss in people with type 2 diabetes who continue their usual Ramadan fasting routine.
This is a Phase 4 interventional study with a single treatment group and no control arm. It is open label, meaning doctors and patients know they are getting tirzepatide, and the main goal is to see how well the drug treats diabetes during the fasting period.
The trial has been marked as completed, showing that all planned participants have finished treatment and follow up. The most recent update on May 20, 2026 signals that Eli Lilly has refreshed key records, often a sign that data cleaning or analysis is moving toward the public results stage.
For investors, this update matters because it targets a specific and growing segment of the global diabetes market, people who fast during Ramadan. Positive outcomes could support broader uptake of tirzepatide in Muslim majority regions and strengthen Lilly’s competitive edge against GLP 1 and dual agonist rivals.
Stronger real world data in challenging settings like fasting can reinforce payer confidence and support premium pricing or faster reimbursement decisions. If results are favorable, investor sentiment for LLY could improve further, while peers in diabetes care may face added pressure to show similar flexibility and effectiveness.
The tirzepatide Ramadan study is now completed and recently updated, with more detailed information available on the ClinicalTrials portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.